Device Trial Radar · NCT06297668
A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer
Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Apr 29, 2024
Primary completion
Jun 11, 2024
Study completion Jun 11, 2024
Sponsor
- Lead sponsor
- AstraZenecaNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Mar 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to assess the effect on total systemic exposure and to characterize exposure BGF MDI HFO with a spacer compared to without a spacer; also, to demonstrate that total systemic exposure of BGF when administered as MDI HFO with a spacer is not greater than BGF MDI HFA with a spacer.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Treatment A: BGF MDI HFADrug
Participants will receive 4 inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer.
Treatment B: BGF MDI HFODrug
Participants will receive 4 inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer.
Treatment C: BGF MDI HFODrug
Participants will receive 4 inhalations of BGF MDI HFO as a single dose without spacer.
AeroChamber Plus Flow-Vu spacerDevice
Participants will receive 4 inhalations of BGF MDI HFA (Treatment A) and BGF MDI HFO (Treatment B) as a single dose with spacer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-curve from Zero to the Last Quantifiable Concentration (AUClast) of BGF MDITime frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
- Maximum Observed Concentration (Cmax) of BGF MDITime frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.